[HTML][HTML] The CD28-transmembrane domain mediates chimeric antigen receptor heterodimerization with CD28
YD Muller, DP Nguyen, LMR Ferreira, P Ho… - Frontiers in …, 2021 - frontiersin.org
Anti-CD19 chimeric antigen receptor (CD19-CAR)-engineered T cells are approved
therapeutics for malignancies. The impact of the hinge domain (HD) and the transmembrane …
therapeutics for malignancies. The impact of the hinge domain (HD) and the transmembrane …
The CD28-transmembrane domain mediates chimeric antigen receptor heterodimerization with CD28
YD Muller, DP Nguyen, LMR Ferreira, P Ho, C Raffin… - bioRxiv, 2020 - biorxiv.org
Anti-CD19 chimeric antigen receptor (CD19-CAR)-engineered T cells are approved
therapeutics for malignancies. The impact of the hinge (HD) and transmembrane (TMD) …
therapeutics for malignancies. The impact of the hinge (HD) and transmembrane (TMD) …
The CD28-Transmembrane Domain Mediates Chimeric Antigen Receptor Heterodimerization With CD28.
YD Muller, DP Nguyen, LMR Ferreira, P Ho… - Frontiers in …, 2021 - europepmc.org
Anti-CD19 chimeric antigen receptor (CD19-CAR)-engineered T cells are approved
therapeutics for malignancies. The impact of the hinge domain (HD) and the transmembrane …
therapeutics for malignancies. The impact of the hinge domain (HD) and the transmembrane …
[HTML][HTML] The CD28-Transmembrane Domain Mediates Chimeric Antigen Receptor Heterodimerization With CD28
YD Muller, DP Nguyen, LMR Ferreira, P Ho… - Frontiers in …, 2021 - frontiersin.org
Anti-CD19 chimeric antigen receptor (CD19-CAR)-engineered T cells are approved
therapeutics for malignancies. The impact of the hinge domain (HD) and the transmembrane …
therapeutics for malignancies. The impact of the hinge domain (HD) and the transmembrane …
[PDF][PDF] The CD28-Transmembrane Domain Mediates Chimeric Antigen Receptor Heterodimerization With CD28
YD Muller, DP Nguyen, LMR Ferreira, P Ho… - Front. Immunol. 12 …, 2021 - academia.edu
Anti-CD19 chimeric antigen receptor (CD19-CAR)-engineered T cells are approved
therapeutics for malignancies. The impact of the hinge domain (HD) and the transmembrane …
therapeutics for malignancies. The impact of the hinge domain (HD) and the transmembrane …
The CD28-Transmembrane Domain Mediates Chimeric Antigen Receptor Heterodimerization With CD28
YD Muller, DP Nguyen, LMR Ferreira… - Frontiers in …, 2021 - pubmed.ncbi.nlm.nih.gov
Anti-CD19 chimeric antigen receptor (CD19-CAR)-engineered T cells are approved
therapeutics for malignancies. The impact of the hinge domain (HD) and the transmembrane …
therapeutics for malignancies. The impact of the hinge domain (HD) and the transmembrane …
[HTML][HTML] The CD28-Transmembrane Domain Mediates Chimeric Antigen Receptor Heterodimerization With CD28
YD Muller, DP Nguyen, LMR Ferreira, P Ho… - Frontiers in …, 2021 - ncbi.nlm.nih.gov
Anti-CD19 chimeric antigen receptor (CD19-CAR)-engineered T cells are approved
therapeutics for malignancies. The impact of the hinge domain (HD) and the transmembrane …
therapeutics for malignancies. The impact of the hinge domain (HD) and the transmembrane …
[PDF][PDF] The CD28-Transmembrane Domain Mediates Chimeric Antigen Receptor Heterodimerization With CD28
YD Muller, DP Nguyen, LMR Ferreira… - Front. Immunol. 12 …, 2021 - researchgate.net
Anti-CD19 chimeric antigen receptor (CD19-CAR)-engineered T cells are approved
therapeutics for malignancies. The impact of the hinge domain (HD) and the transmembrane …
therapeutics for malignancies. The impact of the hinge domain (HD) and the transmembrane …
The CD28-Transmembrane Domain Mediates Chimeric Antigen Receptor Heterodimerization With CD28
YD Muller, DP Nguyen, LMR Ferreira, P Ho… - … in Immunology (Web), 2021 - jglobal.jst.go.jp
Kochenderfer JN Somerville RPT Lu T Shi V Bot A Rossi J. Lymphoma remissions caused
by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin …
by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin …
The CD28-Transmembrane Domain Mediates Chimeric Antigen Receptor Heterodimerization With CD28
YD Muller, DP Nguyen, LMR Ferreira, P Ho, C Raffin… - 2021 - escholarship.org
Anti-CD19 chimeric antigen receptor (CD19-CAR)-engineered T cells are approved
therapeutics for malignancies. The impact of the hinge domain (HD) and the transmembrane …
therapeutics for malignancies. The impact of the hinge domain (HD) and the transmembrane …